Use of Antibody Microarrays in the Analysis of Inflammation, Autoimmunity, Viral Infection, and Cancer Metastases

Lui, Rodney; Brown, Angus; Wu, Bosco; Lin, Ming‐Wei; Thompson, John F.; Braet, Filip; Dyer, Wayne B.; Lattimore, Jo-Dee; Macdonald, Peter M.; Adelstein, Stephen; Remedios, Cristobal G. dos

doi:10.1002/9783527622153.ch31

Clinical Proteomics 2007

DOI: 10.1002/9783527622153.ch31

|View full text |Cite

Use of Antibody Microarrays in the Analysis of Inflammation, Autoimmunity, Viral Infection, and Cancer Metastases

Rodney Lui

Angus Brown

Bosco Wu

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2010

2013

Publication Types

Select...

Article2

Relationship

Self Cite2

Independent0

Authors

Journals

Cited by 2 publications

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Customising an antibody leukocyte capture microarray for systemic lupus erythematosus: Beyond biomarker discovery

Lin

Adelstein

et al. 2010

Proteomics Clinical Apps

Self Cite

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a complex autoimmune disease that has heterogeneous clinical manifestation with diverse patterns of organ involvement, autoantibody profiles and varying degrees of severity of disease. Research and clinical experience indicate that different subtypes of SLE patients will likely benefit from more tailored treatment regimes, but we currently lack a fast and objective test with high enough sensitivity to enable us to perform such sub‐grouping for clinical use. In this article, we review how proteomic technologies could be used as such an objective test. In particular, we extensively review many leukocyte surface markers that are known to have an association with the pathogenesis of SLE, and we discuss how these markers can be used in the further development of a novel SLE‐specific antibody leukocyte capture microarray. In addition, we review some bioinformatics challenges and current methods for using the data generated by these cell‐capture microarrays in clinical use. In a broader context, we hope our experience in developing a disease specific cell‐capture microarray for clinical application can be a guide to other proteomic practitioners who intend to extend their technologies to develop clinical diagnostic and prognostic tests for complex diseases.

show abstract

Customising an antibody leukocyte capture microarray for systemic lupus erythematosus: Beyond biomarker discovery

Lin

Adelstein

et al. 2010

Proteomics Clinical Apps

Self Cite

View full text Add to dashboard Cite

show abstract

An Antibody-Based Leukocyte-Capture Microarray for the Diagnosis of Systemic Lupus Erythematosus

Lin

Harrison

et al. 2013

PLoS ONE

Self Cite

View full text Add to dashboard Cite

The diagnosis of Systemic Lupus Erythematosus (SLE) is challenging due to its heterogeneous clinical presentation and the lack of robust biomarkers to distinguish it from other autoimmune diseases. Further, currently used laboratory tests do not readily distinguish active and inactive disease. Several groups have attempted to apply emerging high throughput profiling technologies to diagnose and monitor SLE. Despite showing promise, many are expensive and technically challenging for routine clinical use. The goal of this work is to develop a better diagnostic and monitoring tool for SLE. We report a highly customisable antibody microarray that consists of a duplicate arrangement of 82 antibodies directed against surface antigens on peripheral blood mononuclear cells (PMBCs). This high-throughput array was used to profile SLE patients (n = 60) with varying disease activity, compared to healthy controls (n = 24), patients with rheumatoid arthritis (n = 25), and other autoimmune diseases (n = 28). We used a computational algorithm to calculate a score from the entire microarray profile and correlated it with SLE disease activity. Our results demonstrate that leukocyte-capture microarray profiles can readily distinguish active SLE patients from healthy controls (AUROC = 0.84). When combined with the standard laboratory tests (serum anti-dsDNA, complements C3 and C4), the microarrays provide significantly increased discrimination. The antibody microarrays can be enhanced by the addition of other markers for potential application to the diagnosis and stratification of SLE, paving the way for the customised and accurate diagnosis and monitoring of SLE.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Use of Antibody Microarrays in the Analysis of Inflammation, Autoimmunity, Viral Infection, and Cancer Metastases

Cited by 2 publications

References 43 publications

Customising an antibody leukocyte capture microarray for systemic lupus erythematosus: Beyond biomarker discovery

Customising an antibody leukocyte capture microarray for systemic lupus erythematosus: Beyond biomarker discovery

An Antibody-Based Leukocyte-Capture Microarray for the Diagnosis of Systemic Lupus Erythematosus

Contact Info

Product

Resources

About